Recombinant human interferon analysis in pharmaceutical formulations
Introduction: Due to the interest in the treatment of hepatitis, the industrial production process of INF-α has been developed and perfected over the last few years. Objective: The present work aimed to develop a protocol to characterize the molecular structure of INF-α2b in pharmaceutical formulati...
| Authors: | , , |
|---|---|
| Format: | article |
| Status: | Published version |
| Publication Date: | 2017 |
| Country: | Brasil |
| Institution: | Fundação Oswaldo Cruz (Fiocruz) |
| Repository: | Vigilância Sanitária em Debate |
| Language: | Portuguese English |
| OAI Identifier: | oai:ojs.visaemdebate.incqs.fiocruz.br:article/943 |
| Online Access: | https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/943 |
| Access Level: | Open access |
| Keyword: | Interferon-alfa Proteínas MALDI-TOF Dicroísmo Circular Fluorescência Alpha Interferon Protein Circular Dichroism Fluorescence |
| Summary: | Introduction: Due to the interest in the treatment of hepatitis, the industrial production process of INF-α has been developed and perfected over the last few years. Objective: The present work aimed to develop a protocol to characterize the molecular structure of INF-α2b in pharmaceutical formulations by MALDI-TOF mass spectrometry. Method: Initially, a reversed-phase liquid chromatography method was developed to promote the separation of active and minor constituent INF-α2b and human serum albumin, also present in the pharmaceutical formulations, to obtain samples with protein homogeneity revealed by electrophoresis. Samples were hydrolyzed with trypsin and submitted to MALDI-TOF. In order to analyze the molecular structure, a procedure based on immunoaffinity and gel filtration chromatography was developed. Results: Prepared samples by these methods showed protein homogeneity by SDS-PAGE, and were analyzed by circular dichroism and fluorescence, which showed three – dimensional structure degradation. Conclusions: This work provides important data that support the establishment of a protocol for the analysis of INF-α2b in final product, which could replace the traditional peptide mapping by liquid chromatography, with the advantage of resulting in a larger amount of information about the structure of the biopharmaceutical. |
|---|